Big Pharma dealmaking has picked up, but the biotech path to a signed agreement is still anything but simple.

In this episode, recorded at Fierce Biotech Week, Senior Editor James Waldron leads a discussion on the evolving BD&L landscape across pharma and biotech.

He is joined by Kaleem Chowdhury, Ph.D., CEO of Haiku Biosciences; Liz Leveille, who leads the Boston Innovation Hub and discovery transactions at Merck; and Abbas Kazemi, CEO of Nimbus Therapeutics.

The panel digs into the realities behind the headlines, from investor scrutiny and platform company pressure to China’s growing role in licensing and the long relationship-building that often happens before a deal gets done.

To learn more about the topics in this episode: 

• March M&A surge triggers high expectations for 2026
• 'Biopharma ecosystem is back to full health,' fueled by M&A: PwC
• Facing mounting China licensing costs, biopharma buyers turn to AI and local know-how to keep up
• After 230% deal size explosion, China is no longer the 'bargain basement' for biopharma licensing: analyst
• Was Big Pharma’s ‘unusually aggressive’ M&A spree to blame for March IPO drought?

This week's episode is sponsored by IQVIA Biotech.

 
Built for biotech innovators, IQVIA Biotech is a full-service CRO, designed for agility, fast decisions, and the urgency needed for emerging biopharma. With dedicated teams and deep therapeutic expertise, we help move programs forward with focus and confidence. Visit IQVIABiotech.com

See omnystudio.com/listener for privacy information.